NEW YORK (Genomeweb News) – Shares of Millipore were up 4 percent at $69.02 in afternoon trade on the New York Stock Exchange after an upgrade to its rating by investment bank Leerink Swann.

The bank raised its rating on Millipore to "outperform" from "market perform." Analyst Isaac Ro said that the change was due to "improving fundamentals and execution."

Millipore "should benefit from exposure to a number of themes that include cell-based H1N1 vaccine production, an improving biologics pipeline, recent product launches, and stimulus funding," wrote Ro.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.